CT-guided needle biopsy is not associated with increased ipsilateral pleural metastasis

IF 4.5 2区 医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2024-07-14 DOI:10.1016/j.lungcan.2024.107890
Benedikt Niedermaier , Yao Kou , Elizabeth Tong , Monika Eichinger , Laura V. Klotz , Martin E. Eichhorn , Thomas Muley , Felix Herth , Hans-Ulrich Kauczor , Claus Peter Heußel , Hauke Winter
{"title":"CT-guided needle biopsy is not associated with increased ipsilateral pleural metastasis","authors":"Benedikt Niedermaier ,&nbsp;Yao Kou ,&nbsp;Elizabeth Tong ,&nbsp;Monika Eichinger ,&nbsp;Laura V. Klotz ,&nbsp;Martin E. Eichhorn ,&nbsp;Thomas Muley ,&nbsp;Felix Herth ,&nbsp;Hans-Ulrich Kauczor ,&nbsp;Claus Peter Heußel ,&nbsp;Hauke Winter","doi":"10.1016/j.lungcan.2024.107890","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Histological confirmation of a lung tumor is the prerequisite for treatment planning. It has been suspected that CT-guided needle biopsy (CTGNB) exposes the patient to a higher risk of pleural recurrence. However, the distance between tumor and pleura has largely been neglected as a possible confounder when comparing CTGNB to bronchoscopy.</p></div><div><h3>Methods</h3><p>All patients with lung cancer histologically confirmed by bronchoscopy or CTGNB between 2010 and 2020 were enrolled and studied. Patients’ medical histories, radiologic and pathologic findings and surgical records were reviewed. Pleural recurrence was diagnosed by pleural biopsy, fluid cytology, or by CT chest imaging showing progressive pleural nodules.</p></div><div><h3>Results</h3><p>In this retrospective unicenter analysis, 844 patients underwent curative resection for early-stage lung cancer between 2010 and 2020. Median follow-up was 47.5 months (3–137). 27 patients (3.2 %) with ipsilateral pleural recurrence (IPR) were identified. The distance of the tumor to the pleura was significantly smaller in patients who underwent CTGNB. A tendency of increased risk of IPR was observed in tumors located in the lower lobe (HR: 2.18 [±0.43], p = 0.068), but only microscopic pleural invasion was a significant independent predictive factor for increased risk of IPR (HR: 5.33 [± 0.51], p = 0.001) by multivariate cox analysis. Biopsy by CTGNB did not affect IPR (HR: 1.298 [± 0.39], p = 0.504).</p></div><div><h3>Conclusion</h3><p>CTGNB is safe and not associated with an increased incidence of IPR in our cohort of patients. This observation remains to be validated in a larger multicenter patient cohort.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169500224004240/pdfft?md5=536fc348ac19e3281b6b25bcc9871d8a&pid=1-s2.0-S0169500224004240-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500224004240","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Histological confirmation of a lung tumor is the prerequisite for treatment planning. It has been suspected that CT-guided needle biopsy (CTGNB) exposes the patient to a higher risk of pleural recurrence. However, the distance between tumor and pleura has largely been neglected as a possible confounder when comparing CTGNB to bronchoscopy.

Methods

All patients with lung cancer histologically confirmed by bronchoscopy or CTGNB between 2010 and 2020 were enrolled and studied. Patients’ medical histories, radiologic and pathologic findings and surgical records were reviewed. Pleural recurrence was diagnosed by pleural biopsy, fluid cytology, or by CT chest imaging showing progressive pleural nodules.

Results

In this retrospective unicenter analysis, 844 patients underwent curative resection for early-stage lung cancer between 2010 and 2020. Median follow-up was 47.5 months (3–137). 27 patients (3.2 %) with ipsilateral pleural recurrence (IPR) were identified. The distance of the tumor to the pleura was significantly smaller in patients who underwent CTGNB. A tendency of increased risk of IPR was observed in tumors located in the lower lobe (HR: 2.18 [±0.43], p = 0.068), but only microscopic pleural invasion was a significant independent predictive factor for increased risk of IPR (HR: 5.33 [± 0.51], p = 0.001) by multivariate cox analysis. Biopsy by CTGNB did not affect IPR (HR: 1.298 [± 0.39], p = 0.504).

Conclusion

CTGNB is safe and not associated with an increased incidence of IPR in our cohort of patients. This observation remains to be validated in a larger multicenter patient cohort.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CT 引导下的针刺活检与同侧胸膜转移增加无关
导言肺部肿瘤的组织学确诊是制定治疗计划的先决条件。人们一直怀疑 CT 引导下针刺活检(CTGNB)会增加患者胸膜复发的风险。然而,在比较 CTGNB 与支气管镜检查时,肿瘤与胸膜之间的距离作为一个可能的混杂因素在很大程度上被忽视了。研究方法:对 2010-2020 年间所有经支气管镜检查或 CTGNB 组织学确诊的肺癌患者进行登记和研究。研究人员回顾了患者的病史、放射学和病理学检查结果以及手术记录。胸膜复发是通过胸膜活检、胸腔积液细胞学检查或胸部CT成像显示进行性胸膜结节来诊断的。中位随访时间为 47.5 个月(3-137)。27名患者(3.2%)出现同侧胸膜复发(IPR)。接受 CTGNB 的患者肿瘤与胸膜的距离明显较小。通过多变量考克斯分析发现,位于下叶的肿瘤发生 IPR 的风险有增加的趋势(HR:2.18 [±0.43],p = 0.068),但只有微小胸膜侵犯才是 IPR 风险增加的重要独立预测因素(HR:5.33 [±0.51],p = 0.001)。CTGNB活检不会影响IPR(HR:1.298 [±0.39],P = 0.504)。这一观察结果还有待在更大规模的多中心患者队列中进行验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lung Cancer
Lung Cancer 医学-呼吸系统
CiteScore
9.40
自引率
3.80%
发文量
407
审稿时长
25 days
期刊介绍: Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.
期刊最新文献
Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer The relevance of the reference range for EGFR testing in non-small cell lung cancer patients Treatment with trimetazidine dihydrochloride and lung cancer survival: Implications on metabolic re-programming
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1